Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Income from Continuing Operations: 2014-2025

Historic Income from Continuing Operations for ImmunityBio (IBRX) over the last 12 years, with Sep 2025 value amounting to -$67.3 million.

  • ImmunityBio's Income from Continuing Operations rose 21.55% to -$67.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$348.7 million, marking a year-over-year increase of 40.68%. This contributed to the annual value of -$413.6 million for FY2024, which is 29.15% up from last year.
  • Per ImmunityBio's latest filing, its Income from Continuing Operations stood at -$67.3 million for Q3 2025, which was up 27.35% from -$92.6 million recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's Income from Continuing Operations peaked at -$59.2 million during Q4 2024, and registered a low of -$233.4 million during Q4 2023.
  • Over the past 3 years, ImmunityBio's median Income from Continuing Operations value was -$116.6 million (recorded in 2023), while the average stood at -$117.0 million.
  • In the last 5 years, ImmunityBio's Income from Continuing Operations plummeted by 115.47% in 2023 and then skyrocketed by 74.65% in 2024.
  • Over the past 5 years, ImmunityBio's Income from Continuing Operations (Quarterly) stood at -$91.6 million in 2021, then decreased by 18.32% to -$108.3 million in 2022, then slumped by 115.47% to -$233.4 million in 2023, then surged by 74.65% to -$59.2 million in 2024, then grew by 21.55% to -$67.3 million in 2025.
  • Its Income from Continuing Operations stands at -$67.3 million for Q3 2025, versus -$92.6 million for Q2 2025 and -$129.7 million for Q1 2025.